NuCana (NCNA) to Release Earnings on Thursday

NuCana (NASDAQ:NCNA) is expected to be announcing its results before the market opens on Thursday, August 13th. Analysts expect NuCana to announce earnings of ($2.6514) per share for the quarter.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.64) by $1.39.

NuCana Stock Down 2.0%

Shares of NCNA stock opened at $1.44 on Tuesday. The firm has a market capitalization of $5.99 million, a P/E ratio of -0.48 and a beta of 2.25. NuCana has a twelve month low of $1.21 and a twelve month high of $7.22. The stock’s fifty day simple moving average is $1.55 and its 200 day simple moving average is $1.91.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.